Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Trevena Price Performance

TRVN stock opened at $1.28 on Monday. The stock has a market capitalization of $1.11 million, a price-to-earnings ratio of -0.03 and a beta of 1.10. The company has a 50-day moving average of $1.35 and a two-hundred day moving average of $1.62. Trevena has a 52-week low of $0.95 and a 52-week high of $11.25.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.